| Literature DB >> 15899038 |
Hing Wo Tsui1, Robert D Inman, Andrew D Paterson, John D Reveille, Florence W L Tsui.
Abstract
The ank (progressive ankylosis) mutant mouse, which has a nonsense mutation in exon 12 of the inorganic pyrophosphate regulator gene (ank), exhibits aberrant joint ankylosis similar to human ankylosing spondylitis (AS). We previously performed family-based association analyses of 124 Caucasian AS families and showed that novel genetic markers in the 5' flanking region of ANKH (the human homolog of the murine ank gene) are modestly associated with AS. The objective of the present study was to conduct a more extensive evaluation of ANKH variants that are significantly associated with AS and to determine whether the association is gender specific. We genotyped 201 multiplex AS families with nine ANKH intragenetic and two flanking microsatellite markers, and performed family-based association analyses. We showed that ANKH variants located in two different regions of the ANKH gene were associated with AS. Results of haplotype analyses indicated that, after Bonferroni correction, the haplotype combination of rs26307 [C] and rs27356 [C] is significantly associated with AS in men (recessive/dominant model; P = 0.004), and the haplotype combination of rs28006 [C] and rs25957 [C] is significantly associated with AS in women (recessive/dominant model; P = 0.004). A test of interaction identified rs26307 (i.e. the region that was associated in men with AS) as showing a difference in the strength of the association by gender. The region associated with AS in women only showed significance in the test of interaction among the subset of families with affected individuals of both genders. These findings support the concept that ANKH plays a role in genetic susceptibility to AS and reveals a gender-genotype specificity in this interaction.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15899038 PMCID: PMC1174945 DOI: 10.1186/ar1701
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Characteristics of 226 nuclear families included in the family-based association studies
| Number of affected siblings | Number of unaffected siblings | Number of unaffected parents | Number of affected parents | Number of nuclear families |
| 2 | 0 | 0 | 0 | 71 |
| 2 | 0 | 2 | 0 | 33 |
| 2 | 0 | 1 | 0 | 14 |
| 2 | 0 | 1 | 1 | 5 |
| 2 | 1 | 0 | 0 | 4 |
| 2 | 2 | 0 | 0 | 3 |
| 2 | 1 | 0 | 1 | 3 |
| 2 | 1 | 2 | 0 | 2 |
| 2 | 2 | 2 | 0 | 1 |
| 3 | 0 | 0 | 0 | 9 |
| 3 | 0 | 2 | 0 | 6 |
| 3 | 0 | 1 | 0 | 4 |
| 3 | 0 | 1 | 1 | 2 |
| 3 | 1 | 0 | 0 | 1 |
| 3 | 1 | 1 | 0 | 1 |
| 4 | 0 | 0 | 0 | 1 |
| 4 | 0 | 2 | 0 | 2 |
| 4 | 0 | 1 | 0 | 1 |
| 4 | 1 | 2 | 0 | 1 |
| 1 | 0 | 2 | 0 | 25 |
| 1 | 0 | 1 | 1 | 8 |
| 1 | 0 | 1 | 0 | 2 |
| 1 | 0 | 0 | 1 | 7 |
| 1 | 1 | 0 | 0 | 3 |
| 1 | 1 | 0 | 1 | 3 |
| 1 | 1 | 2 | 0 | 1 |
| 1 | 1 | 1 | 1 | 1 |
| 1 | 2 | 0 | 0 | 1 |
| 1 | 2 | 0 | 1 | 1 |
| 1 | 2 | 2 | 0 | 1 |
| 1 | 3 | 0 | 0 | 1 |
| 1 | 3 | 2 | 0 | 1 |
| 0 | 2 | 0 | 0 | 1 |
| 0 | 2 | 1 | 1 | 2 |
| 0 | 1 | 0 | 1 | 3 |
Gender information for affected individuals in the 201 ankylosing spondylitis families
| Number of affected men/women in a family | Number of families |
| Families with both affected men and women | 94 |
| 1/1 | 60 |
| 2/1 | 17 |
| 3/1 | 1 |
| 1/2 | 8 |
| 2/2 | 3 |
| 3/2 | 1 |
| 1/3 | 2 |
| 2/3 | 2 |
| Families with only affected men | 74 |
| 1/0 | 5 |
| 2/0 | 54 |
| 3/0 | 12 |
| 4/0 | 2 |
| 5/0 | 1 |
| Families with only affected women | 33 |
| 0/1 | 2 |
| 0/2 | 26 |
| 0/3 | 4 |
| 0/4 | 1 |
Figure 1Locations and spacings of genetic markers used for genotyping. D5S1991 and ANKH-OR are located at the 5' flanking region of ANKH. All seven single nucleotide polymorphisms used are located in the introns of ANKH.
FBAT-e analyses conducted in 226 ankylosing spondylitis nuclear families (201 pedigrees, 894 persons)
| Marker | Allele | Allele frequency | Number of informative families | Z score | |
| Additive model: biallelic test | |||||
| | 2 | 0.45 | 54 | 0.57 | 0.569 |
| | C | 0.81 | 35 | 1.73 | 0.084 |
| | C | 0.80 | 39 | 2.54 | 0.011* |
| | G | 0.79 | 28 | 1.28 | 0.198 |
| | A | 0.76 | 48 | 1.61 | 0.107 |
| | A | 0.59 | 43 | 1.58 | 0.113 |
| | C | 0.74 | 34 | 1.62 | 0.104 |
| | C | 0.76 | 36 | 2.02 | 0.043* |
| | 1 | 0.47 | 59 | 1.62 | 0.105 |
| | 2 | 0.48 | 58 | 1.33 | 0.181 |
| | 1 | 0.64 | 54 | 0.65 | 0.515 |
| Recessive model: biallelic test | |||||
| | 2 | 0.43 | 48 | 0.45 | 0.683 |
| | C | 0.80 | 40 | 1.49 | 0.137 |
| | C | 0.79 | 44 | 2.32 | 0.020* |
| | G | 0.79 | 31 | 1.19 | 0.233 |
| | A | 0.76 | 50 | 1.86 | 0.062 |
| | A | 0.58 | 32 | 1.55 | 0.120 |
| | C | 0.74 | 37 | 1.46 | 0.142 |
| | C | 0.76 | 38 | 1.65 | 0.098 |
| | 2 | 0.52 | 37 | -2.20 | 0.027* |
| | 1 | 0.52 | 45 | -1.96 | 0.050* |
| | 1 | 0.64 | 54 | 0.65 | 0.517 |
*Statistically significant findings. FBAT, family-based association testing.
Figure 2Age of diagnosis for (a) men and (b) women in the North American multiplex ankylosing spondilitis families.
FBAT-e analyses using setafftrait 0 -1 0, testing specifically for affected women
| Marker | Allele | Allele frequency | Number of informative families | Z score | |
| Additive model: biallelic test | |||||
| | 1 | 0.56 | 47 | 0.47 | 0.635 |
| | T | 0.19 | 22 | 0.32 | 0.751 |
| | T | 0.20 | 24 | 1.03 | 0.302 |
| | C | 0.21 | 20 | 0.37 | 0.712 |
| | G | 0.24 | 46 | 1.31 | 0.191 |
| | T | 0.41 | 30 | 1.54 | 0.123 |
| | T | 0.26 | 31 | 2.82 | 0.004* |
| | G | 0.23 | 23 | 2.82 | 0.004* |
| | 2 | 0.52 | 59 | 0.94 | 0.347 |
| | 1 | 0.52 | 53 | 1.10 | 0.270 |
| | 2 | 0.36 | 45 | 1.38 | 0.168 |
| Recessive model: biallelic test | |||||
| | 2 | 0.44 | 39 | -1.21 | 0.227 |
| | C | 0.81 | 26 | 0.52 | 0.606 |
| | T | 0.20 | 10 | 1.81 | 0.069 |
| | G | 0.79 | 22 | 0.08 | 0.930 |
| | A | 0.76 | 44 | -1.39 | 0.162 |
| | A | 0.58 | 21 | -1.76 | 0.077 |
| | C | 0.74 | 28 | -2.49 | 0.012* |
| | C | 0.76 | 23 | -2.25 | 0.024* |
| | 2 | 0.52 | 34 | 1.14 | 0.254 |
| | 1 | 0.51 | 33 | 1.52 | 0.127 |
| | 1 | 0.64 | 45 | -1.54 | 0.122 |
*Statistically significant findings. FBAT, family-based association testing.
FBAT-e analyses using setafftrait 1 0 0, testing specifically for affected men
| Marker | Allele | Allele frequency | Number of informative families | Z score | |
| Additive model: biallelic test | |||||
| | 2 | 0.44 | 47 | 0.25 | 0.805 |
| | C | 0.80 | 22 | 2.06 | 0.039* |
| | C | 0.79 | 25 | 2.63 | 0.008* |
| | G | 0.79 | 18 | 1.23 | 0.216 |
| | A | 0.76 | 36 | 0.49 | 0.619 |
| | A | 0.58 | 32 | 0.81 | 0.419 |
| | T | 0.26 | 37 | 0.15 | 0.877 |
| | C | 0.77 | 33 | 0.76 | 0.446 |
| | 1 | 0.48 | 64 | 1.04 | 0.297 |
| | 2 | 0.49 | 64 | 0.39 | 0.696 |
| | 2 | 0.36 | 49 | 0.33 | 0.736 |
| Recessive model: biallelic test | |||||
| | 1 | 0.56 | 40 | -0.83 | 0.406 |
| | C | 0.81 | 25 | 2.51 | 0.012* |
| | C | 0.80 | 28 | 2.99 | 0.002* |
| | G | 0.79 | 22 | 1.44 | 0.149 |
| | A | 0.76 | 39 | 0.71 | 0.477 |
| | A | 0.59 | 23 | 0.60 | 0.543 |
| | T | 0.26 | 16 | 0.33 | 0.739 |
| | C | 0.76 | 29 | 0.64 | 0.518 |
| | 2 | 0.52 | 44 | -1.26 | 0.205 |
| | 1 | 0.51 | 46 | -0.71 | 0.472 |
| | 1 | 0.64 | 43 | -0.65 | 0.510 |
*Statistically significant findings. FBAT, family-based association testing.
HBAT-e analyses using ANKH markers in four haplotype blocks defined in HapMap
| Markers in the haplotype block | AS nuclear families (n = 226) | Testing specifically for affected women | Testing specifically for affected men |
| Additive model | |||
| | [C,C]; 0.78; 39; 0.04 | NS | [C,C]; 0.79; 24; 0.014 |
| | NS | NS | NS |
| | NS | [T,G]; 0.25; 19; 0.007 | NS |
| | [1,2]; 0.43; 57; 0.013 | NS | NS |
| Recessive/dominant model | |||
| | [C,C]; 0.78; 40; 0.02 | NS | [C,C]; 0.79; 25; 0.004* |
| | [G,A]; 0.70; 32; 0.02 | NS | NS |
| | NS | [C,C]; 0.71; 18; 0.004* | NS |
| | NS | NS | NS |
Data are expressed as [allele]; allele frequency; number of informative families; P value.
*Significant P value after Bonferroni correction. (Because eight tests [four haplotypes and two models] were carried out in the haplotype-based association testing [HBAT]-e analyses, P < 0.00625 [0.05/8] is considered statistically significant.) AS, ankylosing spondylitis; NS, not significant.
FBAT-e analyses considering 226 ankylosing spondylitis nuclear families (201 pedigrees, 894 persons): summary of results using setafftrait 1 -1 0
| Marker | Allele | Allele frequency | Number of informative families | Z score | |
| Additive model: biallelic test | |||||
| | 1 | 0.56 | 63 | 0.15 | 0.879 |
| | C | 0.81 | 35 | 1.29 | 0.195 |
| | C | 0.80 | 39 | 1.12 | 0.261 |
| | G | 0.79 | 29 | 0.69 | 0.489 |
| | G | 0.24 | 52 | 0.61 | 0.541 |
| | T | 0.41 | 41 | 0.46 | 0.638 |
| | T | 0.26 | 44 | 1.69 | 0.090 |
| | G | 0.23 | 39 | 0.90 | 0.366 |
| | 1 | 0.48 | 80 | 0.20 | 0.841 |
| | 1 | 0.52 | 80 | 0.29 | 0.769 |
| | 2 | 0.36 | 63 | 1.21 | 0.227 |
| Recessive model: biallelic test | |||||
| | 1 | 0.56 | 46 | -0.89 | 0.370 |
| | C | 0.81 | 37 | 2.17 | 0.030* |
| | C | 0.80 | 41 | 1.91 | 0.055 |
| | G | 0.79 | 29 | 1.17 | 0.240 |
| | G | 0.24 | 18 | 0.55 | 0.582 |
| | A | 0.59 | 29 | -0.75 | 0.453 |
| | C | 0.74 | 40 | -1.13 | 0.186 |
| | C | 0.77 | 36 | -0.66 | 0.507 |
| | 2 | 0.52 | 50 | -0.34 | 0.733 |
| | 2 | 0.49 | 52 | -0.28 | 0.779 |
| | 1 | 0.64 | 61 | -1.53 | 0.126 |
*Statistically significant findings. FBAT, family-based association testing.
FBAT-e analyses considering 108 ankylosing spondylitis nuclear families (94 pedigrees, 425 persons) in which both affected men and women are present in each family: summary of the results using setafftrait 1 -1 0
| Marker | Allele | Allele frequency | Number of informative families | Z score | |
| Additive model: biallelic test | |||||
| | 1 | 0.56 | 39 | 0.77 | 0.437 |
| | C | 0.90 | 10 | 0.50 | 0.617 |
| | C | 0.77 | 17 | 0.15 | 0.875 |
| | C | 0.21 | 13 | 0.63 | 0.527 |
| | G | 0.23 | 32 | 0.81 | 0.418 |
| | T | 0.49 | 21 | 1.62 | 0.104 |
| | T | 0.29 | 27 | 2.81 | 0.004* |
| | G | 0.32 | 22 | 2.37 | 0.017* |
| | 1 | 0.48 | 51 | 0.25 | 0.801 |
| | 2 | 0.50 | 48 | 0.13 | 0.891 |
| | 2 | 0.33 | 31 | 1.13 | 0.254 |
| Recessive model: biallelic test | |||||
| | 2 | 0.44 | 31 | -1.34 | 0.177 |
| | C | 0.79 | 19 | 1.00 | 0.314 |
| | C | 0.80 | 20 | 1.17 | 0.239 |
| | G | 0.79 | 14 | -0.26 | 0.788 |
| | G | 0.23 | 10 | 1.06 | 0.288 |
| | A | 0.51 | 12 | -2.49 | 0.012* |
| | C | 0.71 | 20 | -2.344 | 0.019* |
| | C | 0.67 | 15 | -1.97 | 0.048* |
| | 1 | 0.48 | 27 | 0.83 | 0.406 |
| | 2 | 0.49 | 29 | 0.98 | 0.322 |
| | 1 | 0.66 | 31 | -1.67 | 0.093 |
*Statistically significant findings. FBAT, family-based association testing.